Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Down 60.7% in April

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a large drop in short interest in April. As of April 30th, there was short interest totaling 2,682 shares, a drop of 60.7% from the April 15th total of 6,831 shares. Based on an average daily trading volume, of 87,964 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are sold short.

Santen Pharmaceutical Stock Up 2.9%

Shares of OTCMKTS SNPHY traded up $0.34 during trading hours on Thursday, hitting $11.90. 1,062 shares of the stock were exchanged, compared to its average volume of 15,644. The company has a market cap of $3.84 billion and a PE ratio of 0.10. The firm has a fifty day moving average price of $10.87 and a 200-day moving average price of $10.69. Santen Pharmaceutical has a 12 month low of $9.22 and a 12 month high of $12.68.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.